Praxis Precision Medicines, Inc. (PRAX)

Market Cap	1.47B
Revenue (ttm)	1.61M
Net Income (ttm)	-151.02M
Shares Out	19.25M
EPS (ttm)	-9.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	347,462
Open	74.61
Previous Close	74.02
Day's Range	74.45 - 76.55
52-Week Range	33.01 - 86.93
Beta	2.68
Analysts	Strong Buy
Price Target	149.11 (+95.68%)
Earnings Date	Mar 4, 2025

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 82
• Stock Exchange: NASDAQ
• Ticker Symbol: PRAX
• Website: https://praxismedicines.com

Analyst Forecast

According to 9 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price forecast is $149.11, which is an increase of 95.68% from the latest price.

Price Target

$149.11

(95.68% upside)

Analyst Consensus: Strong Buy